Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Minoxidil
Drug ID BADD_D01473
Description A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure.
Indications and Usage For the treatment of severe hypertension and in the topical treatment (regrowth) of androgenic alopecia in males and females and stabilisation of hair loss in patients with androgenic alopecia.
Marketing Status approved; investigational
ATC Code C02DC01; D11AX01
DrugBank ID DB00350
KEGG ID D00418
MeSH ID D008914
PubChem ID 4201
TTD Drug ID D0Y2CJ
NDC Product Code 73277-002; 82607-002; 83454-404; 0591-5642; 38779-0574; 11673-317; 30142-632; 0113-7798; 41163-798; 41250-749; 49035-905; 56062-798; 57483-540; 57483-542; 63940-385; 64942-2111; 68016-382; 69113-128; 71713-091; 71730-023; 72288-701; 72764-002; 72789-278; 79481-0070; 79903-072; 46204-0159; 54236-020; 11822-0114; 11822-0702; 30142-719; 51316-212; 53489-387; 57483-535; 63940-582; 63981-032; 69968-0031; 69968-0089; 71205-757; 71730-798; 72288-202; 72789-279; 72882-094; 81653-002; 82157-200; 82987-101; 83383-398; 0591-5643; 63934-007; 67438-020; 71052-063; 11509-0798; 11673-157; 11673-189; 11673-382; 11822-0606; 11822-0798; 0113-7202; 41250-202; 41250-428; 51326-160; 59450-211; 0363-0703; 68391-302; 69423-559; 69842-599; 70550-605; 72162-1490; 72484-096; 63629-1085; 65121-101; 68196-032; 71205-490; 71730-000; 72288-129; 72288-294; 72764-001; 81632-408; 82157-100; 82269-607; 40700-0008; 79572-022; 21130-273; 21130-750; 0113-1032; 49035-746; 49884-257; 50663-395; 53489-386; 56062-202; 56062-294; 63629-9299; 63629-9620; 64942-2110; 68084-204; 68391-294; 69113-129; 69423-586; 69842-598; 73277-001; 82429-200; 66219-0004; 67438-015; 11673-632; 11822-1033; 0113-0294; 0113-7129; 0113-7294; 37808-202; 41250-294; 51326-165; 56062-070; 0363-0032; 63629-1086; 0363-9090; 0363-9971; 63940-491; 63940-509; 63981-380; 63981-798; 65121-562; 68196-823; 69282-001; 69423-587; 81653-001; 81653-003; 81653-005; 17337-0027; 49452-4780; 51552-1334; 68981-036; 11673-707; 11822-0202; 11822-1323; 25280-006; 30142-294; 0113-7032; 37808-798; 43353-342; 51316-213; 63629-2230; 63629-2232; 0363-9091; 0363-9973; 63940-202; 69423-558; 69842-797; 70518-3419; 72484-095; 0009-5056; 62991-1105; 64162-0210; 11673-158; 11673-798; 11673-919; 0113-0798; 51326-161; 51672-2129; 55301-094; 56062-322; 59640-000; 59779-294; 0363-9972; 63940-032; 63981-294; 68788-8273; 69282-002; 71713-092; 71713-093; 71713-094; 72288-798; 81653-004; 51927-2885; 73005-0008; 80813-0022; 11673-431; 11822-0115; 41250-798; 42291-619; 49884-256; 51672-2128; 57483-530; 59726-115; 0363-2294; 0363-9970; 65121-102; 68196-469; 69968-0090; 71176-781; 71730-129; 71730-202; 71730-294; 82157-002; 82376-6006; 82376-6007; 0009-5230; 51552-0536; 11822-0129; 11822-1260; 25280-007; 0113-1129; 61269-094; 0363-1129; 0363-2798; 63629-2231; 63629-9433; 68016-006; 68084-205; 69968-0030; 71290-813; 80855-201; 81653-006; 82157-001; 82796-100; 10695-149; 76003-0748; 21130-163; 21130-819; 37808-833; 42291-618; 49035-294; 49539-001; 51326-166; 59450-210; 59726-116; 59779-202
UNII 5965120SH1
Synonyms Minoxidil | Rogaine | Regaine | U 10858 | Loniten
Chemical Information
Molecular Formula C9H15N5O
CAS Registry Number 38304-91-5
SMILES C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Adverse event08.06.01.010---
Breast disorder21.05.04.004---
Cardiac disorder02.11.01.0030.003297%-
Malnutrition14.03.02.004---
Mediastinal disorder22.09.03.001---
Erectile dysfunction19.08.04.001; 21.03.01.007--
Blood disorder01.05.01.004---
Chorioretinopathy06.09.01.0060.002806%-
Application site exfoliation08.02.01.022; 12.07.01.022; 23.03.07.0070.004770%-
Acute kidney injury20.01.03.0160.003157%
Application site haemorrhage08.02.01.040; 12.07.01.040; 24.07.01.0480.002385%-
Sinus node dysfunction02.03.03.0170.000701%
Occupational asthma10.01.03.045; 22.03.01.0240.001052%-
Drug effective for unapproved indication08.06.01.037; 12.09.02.0010.000701%-
Drug ineffective for unapproved indication08.06.01.038; 12.09.02.0020.007856%-
Eosinophilic pleural effusion01.02.04.023; 22.05.02.0090.001894%-
Psychotic symptom19.03.01.0120.000701%-
Subendocardial ischaemia02.02.02.027; 24.04.04.0330.000701%-
Therapy partial responder08.06.01.0640.000701%-
The 5th Page    First    Pre   5    Total 5 Pages